期刊
THROMBOSIS RESEARCH
卷 125, 期 -, 页码 S52-S56出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.thromres.2010.01.038
关键词
Tissue factor pathway inhibitor; Blood coagulation; Alternative splicing; Translational regulation
资金
- NHLBI [R01HL068835, K01HL096419]
Tissue factor pathway inhibitor (TFPI) is the major regulator of tissue factor (TF)-induced coagulation. It down regulates coagulation by binding to the TF/fVIIa complex in a fXa dependent manner. It is predominantly produced by microvascular endothelial cells, though it is also found in platelets, monocytes, smooth muscle cells, and plasma. Its physiological importance is demonstrated by the embryonic lethality observed in TFPI knockout mice and by the increase in thrombotic burden that occurs when heterozygous TFPI mice are bred with mice carrying genetic risk factors for thrombotic disease, such as factor V Leiden. Multiple TFPI isoforms, termed TFPI alpha, TFPI beta, and TFPI delta in humans and TFPI alpha, TFPI beta, and TFP gamma in mice, have been described, which differ in their domain structure and method for cell surface attachment. A significant functional difference between these isoforms has yet to be described in vivo. Both human and mouse tissues produce, on average, approximately 10 times more TFPI alpha message when compared to that of TFPI beta. Consistent with this finding, several lines of evidence suggest that TFPI alpha is the predominant protein isoform in humans. In contrast, recent work from our laboratory demonstrates that TFPI beta is the major protein isoform produced in adult mice, suggesting that TFPI isoform production is translationally regulated. (C) 2010 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据